Monopar Therapeutics (MNPR +7.8%) and NorthStar Medical Radioisotopes submits a provisional patent application for precision radioimmunotherapeutic targeting Urokinase Plasminogen Activator Receptor (uPAR) for the treatment of COVID-19.
Earlier, Monopar and NorthStar inked a collaboration to couple Monopar’s MNPR-101 uPAR targeting monoclonal antibody to a therapeutic radioisotope provided by NorthStar.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.